BNTC Stock Summary and Trading Ideas (Benitec Biopharma | NASDAQ:BNTC)

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Benitec Biopharma trades on the NASDAQ stock market under the symbol BNTC.

As of September 11, 2026, BNTC stock price declined to $12.19 with 85,962 million shares trading.

BNTC has a beta of 2.15, meaning it tends to be more sensitive to market movements. BNTC has a correlation of 0.22 to the broad based SPY ETF.

BNTC has a market cap of $418.78 million. This is considered a Small Cap stock.

In the last 3 years, BNTC traded as high as $17.15 and as low as $2.69.

The top ETF exchange traded funds that BNTC belongs to (by Net Assets): PINK, VTI, VXF, VTWO, GNOM.

BNTC has underperformed the market in the last year with a price return of -12.8% while the SPY ETF gained +17.4%. However, in the short term, BNTC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.3% vs +3.9% return in SPY. But in the last 2 weeks, BNTC shares have been beat by the market, returning -2.2% compared to an SPY return of -0.7%.

BNTC support price is $11.75 and resistance is $12.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTC shares will trade within this expected range on the day.